Skip to main content
Full access
New Research
Published Online: 1 October 2010

The Effects of Antidepressant Step Therapy Protocols on Pharmaceutical and Medical Utilization and Expenditures

Abstract

Objective:

This study examined the effects of step therapy for antidepressants on prescription drug and other medical utilization and spending. Step therapy is a type of pharmaceutical benefit design that requires that patients try certain specified medications (typically generic medications) prior to using alternative, more expensive medications within the same medication class. Step therapy is not the same as generic substitution.

Method:

Using the 2003–2006 Thomson Reuters MarketScan claims databases, antidepressant users enrolled in employer plans that implemented antidepressant step therapy were compared with antidepressant users enrolled in employer plans that had not implemented step therapy. Multivariate generalized estimating equation models were used to analyze the relationship between step therapy for antidepressants and 1) pharmacy and medical utilization and 2) spending.

Results:

Antidepressant days supplied and medication costs decreased after step therapy was implemented, relative to the comparison group. However, overall and mental health-specific inpatient and emergency room utilization and costs increased.

Conclusions:

Step therapy may have the unintended effect of reducing overall antidepressant use and increasing medical use and costs.

Formats available

You can view the full content in the following formats:

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1202 - 1209
PubMed: 20713497

History

Received: 23 June 2009
Revision received: 17 November 2009
Revision received: 7 January 2010
Accepted: 18 March 2010
Published online: 1 October 2010
Published in print: October 2010

Authors

Affiliations

Tami L. Mark, Ph.D.
From Thomson Reuters and Pfizer, Inc.
Teresa M. Gibson, Ph.D.
From Thomson Reuters and Pfizer, Inc.
Kimberly McGuigan, Ph.D.
From Thomson Reuters and Pfizer, Inc.
Bong Chul Chu, Ph.D.
From Thomson Reuters and Pfizer, Inc.

Notes

Address correspondence and reprint requests to Dr. Mark, Thomson Reuters, 4301 Connecticut Ave., NW, Suite 330, Washington, DC 20008; [email protected] (e-mail).

Funding Information

Funded by Pfizer, Inc.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Full Text

View Full Text

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share